|
KMID : 1143120140040030156
|
|
Asia Pacific Allergy
2014 Volume.4 No. 3 p.156 ~ p.163
|
|
|
A retrospective study on sequential desensitization-rechallenge for antituberculosis drug allergy
|
|
Thong Bernard Yu-Hor
Chia Faith Li-Ann
Tan Sze-Chin
Tan Teck-Choon
Leong Khai-Pang
Tan Justina Wei-Lyn
Tang Chwee-Ying
Hou Jin-Feng
Chan Grace Yin-Lai
Chng Hiok-Hee
|
|
|
Abstract
|
|
|
Background: Antituberculosis (anti-TB) drug allergy often involves multiple concurrently administered drugs which subsequently need to be reinitiated as no better alternatives exist.
Objective: To describe the results of tailored sequential desensitization-rechallenge (D-R) for anti-TB drug allergy.
Methods: Consecutive patients who had undergone D-R to anti-TB drugs between 1 September 1997 and 31 January 2012 were recruited. Following resolution of the acute reaction, anti-TB drug was restarted at 1:6,000 to 1:3 of the final daily dose (FDD), with gradual single or multiple step daily dose escalation to the FDD. Subsequent drugs were sequentially added ≥3 days later when the preceding drug was tolerated. Full blood count and liver function tests were monitored prior to addition of each new drug.
Results: There were 11 patients of whom 10 were male, predominantly Chinese (8 patients). Regimens comprised at least 3 drugs: isoniazid (INH), rifampicin (RIF), ethambutol (EMB), pyrazinamide (PZA), or streptomycin. All patients had nonimmediate reactions, with cutaneous eruptions, where maculopapular exanthema (MPE) was the most common (8 patients). Drug-induced hypersensitivity syndrome (DIHS) occurred in 6 patients, and Stevens Johnson syndrome (SJS) in 2 patients. D-R to INH was successful in 7/9 patients (77.8%) and to RIF/EMB/PZA/streptomycin in all. Of the 2 patients who failed INH D-R, 1 developed fever and MPE on day 3, the other MPE on day 8. D-R with INH and RIF respectively was successful in 2 patients with SJS. Among DIHS patients, 1 failed D-R with INH (fever and MPE on day 3). There were 23/25 (92%) successful D-R among the 11 patients. All patients completed TB treatment of ≥5 months' duration with no cases of drug-resistant TB.
Conclusion: Tailored sequential TB drug D-R is successful where no better alternative therapies are available, with careful dose escalation and close monitoring, and after a careful risk-benefit assessment.
|
|
|
KEYWORD
|
|
|
Allergy, Desensitization, Drug eruptions, Drug hypersensitivity syndrome
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|